Zhi Tong Cai Jing·2025-08-20 02:35Core Viewpoint - Nocera Biotech (09969) experienced a decline of over 4% following the release of its interim results, with shares trading at HKD 19.01 and a transaction volume of HKD 66.54 million [1] Financial Performance - For the six months ending June 30, 2025, Nocera Biotech reported revenue of RMB 731 million, representing a year-on-year increase of 74.26% [1] - The adjusted loss for the period was RMB 15.504 million, a decrease of 93.62% compared to the previous year [1] - The loss attributable to the company's owners was RMB 30.091 million, down 88.51% year-on-year [1] - The loss per share was RMB 0.02 [1] Revenue Drivers - The increase in revenue was primarily driven by strong sales growth of Oubutini and licensing income from Prolium [1] - Revenue from Oubutini rose from RMB 417 million for the six months ending June 30, 2024, to RMB 637 million for the same period in 2025, marking a 52.8% increase due to expanded coverage and an increase in treated patients [1]